Nektar Therapeutics (NKTR) Operating Expenses (2010 - 2026)

Nektar Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $49.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 1018.92% year-over-year to $49.9 million in Q1 2026; TTM through Mar 2026 was $147.0 million, a 219.76% increase from a year earlier, with the FY2025 full-year figure at $195.3 million, up 422.19% from the prior year.
• Operating Expenses grew to $49.9 million in Q1 2026 per NKTR's latest filing, from $49.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $174.4 million in Q2 2022 and bottomed at -$151.4 million in Q4 2024.
• The 5-year median for Operating Expenses is $49.9 million (2026), against an average of $41.1 million.
• Across the five-year window, Operating Expenses tumbled 297.43% in 2023 and jumped 1018.92% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $74.5 million in 2022, then tumbled by 297.43% to -$147.1 million in 2023, then declined by 2.94% to -$151.4 million in 2024, then surged by 132.68% to $49.5 million in 2025, then advanced by 0.9% to $49.9 million in 2026.
• Per Business Quant, the three latest NKTR Operating Expenses figures stand at $49.9 million (Q1 2026), $49.5 million (Q4 2025), and $43.5 million (Q3 2025).